Q&A: A missing conversation on the price of cancer drugs
13 May 2016
A novel approach to judge which new cancer drugs are worth reimbursing is emerging within the European Organisation for Research and Treatment of Cancer, an independent research group. Denis Lacombe, its director general, says the growing understanding of tumor biology can equip European authorities to make more informed decisions based on performance in real-life conditions. In an interview with POLITICO, he suggested how to ease access to the evidence that could radically improve decision-making.
The read the full article on the Politico Pro website.
Related News
First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer
28 Oct 2026
EORTC at ESMO 2026: New findings and ongoing studies
27 Oct 2026
EORTC research presented at ESMO 2026
22 Oct 2026
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
